OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Drug Safety is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	43
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	32
Adverse drug reactions associated with glycyrrhiza-containing Chinese patent medicines: a literature-based analysis of individual case reports and clinical trials	31
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	29
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	25
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	24
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study	20
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	20
Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record	18
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	16
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	15
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	15
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System	15
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	13
Prevalence of potentially inappropriate medication use and its association with hospitalization among older adults with chronic disease in the Amhara region, Ethiopia: a multicenter prospective cohort	13
Machine learning risk prediction models for medication harm in hospitalised adult patients	13
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	13
Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling	13
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	12
Disparities and trends in drug-related adverse reaction mortality in the United States, 1999–2020	12
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	11
Complex chronic adverse events following immunization: a systemic critique and reform proposal for vaccine pharmacovigilance	11
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	10
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	10
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	10

The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	9
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	9
Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study	9
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	9
Impact of risk communication on patient’s safety during the pandemic	8
Impact of social determinants of health on safety of patients in device clinical trials conducted at a safety-net hospital	8
Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer	8
Treating hearts and minds: adverse cardiovascular effects of psychiatric medications	7
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	7
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts	7
Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal	7
Artificial intelligence in drug development: reshaping the therapeutic landscape	7
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	7
Data mining results for reduction of adverse drug–drug interaction events in older adults are clinically applicable	7
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	7
Efficacy and safety of ciprofol versus propofol for sedation in hysteroscopy: a systematic review and meta-analysis	6
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	6
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries	6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	6
Probable case of anaphylaxis due to hydrocortisone in a septic shock patient	6
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization	6
The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System	6
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	6
Machine learning studies of drug-induced nephrotoxicity: a scoping review	6
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	6
Team approach to polypharmacy evaluation and reduction for general practice patients with dementia: the Australian TAPERDem study	6
Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study	5
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met	5
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries	5
Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity	5
Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial	5
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database	5
Impact of clinical pharmacist involvement on emergency department physicians’ work-time distribution: a comparative analysis	5
How is AI developing in pharmacovigilance?	5
A descriptive, retrospective analysis of the quality of spontaneous adverse event reporting to the Côte d’Ivoire Pharmaceutical and Regulatory Authority and its impact on the causality assessment	5
Is there a risk of esketamine misuse in clinical practice?	5
Effect of ciprofol-assisted sedation on tourniquet-related responses in foot and ankle surgery: a randomized clinical trial	5
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients	4
The effects of Dexmedetomidine on Recovery from Acute KIdney INjury (DRAIN): a single-center retrospective review using the Medical Information Mart for Intensive Care, fourth edition (MIMIC-IV)	4
Development and prospective validation of a machine learning model for risk stratification of drug-induced liver injury using real-world clinical data	4
Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects	4
Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System	4
Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System	4
Reflections, operational lessons, and practical insights from a pharmacovigilance inspection: a case example of organizational strategies for medical safety readiness	4
Pharmacovigilance analysis of small bowel bleeding associated with NSAIDs	4
Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib	4
Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries	4
Sequential analysis for post-marketing drug safety surveillance using routinely collected electronic healthcare data: a scoping review	4
Monitoring of QTc in subjects hospitalized for 1 year in an acute psychiatric ward treated with clotiapine and other associated antipsychotics: a retrospective study	4
Increasing risk of hemorrhage following concurrent use of Salvia miltiorrhiza and oral anticoagulants: a retrospective self-controlled case series study	4

Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study	3
Characterizing medication safety incidents in surgical patients: a retrospective cross-sectional analysis of incident reports	3
Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database	3
Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study	3
Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis	3
Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System	3
Rebound hypertension following prolonged oxymetazoline use: a signal-generating case report	3
Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review	3
Developing and testing of an assessment tool for appropriate psychotropic drug prescribing in people with intellectual disabilities	2
A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)	2
Comparison of pharmacovigilance and mechanism analysis of the vascular toxicity caused by platin-based chemotherapy: integration of FAERS analysis, network pharmacology, and endothelial validation	2
Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review	2
Orchestrating generative AI in pharmacovigilance: predicting and preempting the unpredictable	2
Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis	2
Developing and piloting a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice	2
Investigating the impact of a pharmacist intervention on inappropriate prescribing practices at hospital admission and discharge in older patients: a secondary outcome analysis from a randomized contr	2
Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER	2
Can large language models detect drug–drug interactions leading to adverse drug reactions?	2
Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review	2
Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 2020	2
Determinants of COVID-19 vaccine-induced myocarditis	2
The 6th European Pharmacovigilance Congress: speaker abstracts	2
Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan	2
An integrative systematic review of nurses’ involvement in medication deprescription in long-term healthcare settings for older people	2
Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?	2
Muscle relaxant use and the associated risk of Sjögren’s syndrome and dry eye disease (including keratoconjunctivitis sicca) in patients with ankylosing spondylitis: a population-based cohort study	2
Beyond pain relief: the thrombosis threat of celecoxib	2
Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert	2
Detection of clinically significant drug-drug interactions in serotonin syndrome: a multisource real-world data and pharmacovigilance study	2
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature	2
Incidence, risk factors, and prediction model of piperacillin/tazobactam-associated hypokalemia in neonates	2